CYT 1010

Drug Profile

CYT 1010

Alternative Names: Cyt-1010

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Tulane University
  • Developer Cytogel
  • Class Analgesics; Peptides
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Pain

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Pain(In volunteers) in USA
  • 14 Nov 2014 CYT 1010 is available for licensing as of 14 Nov 2014. http://www.cytogelpharma.com/partnership-opportunity.html
  • 28 Oct 2011 Adverse events & pharmacodynamics data from a phase I trial in Healthy volunteers presented at the American Society of Anesthesiologists Annual Meeting (ASA-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top